Atlas Trials

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Clinical trial NCT02839720 · COMPLETED

Trial details

NCT number
NCT02839720
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cutaneous NeurofibromaNeurofibromatosis Type 1Optic Nerve Glioma
Start date
2017-08-26
Primary completion
2022-11-05
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.